Halozyme to acquire Elektrofi for $900m.

Halozyme, a biopharmaceutical company, agreed to acquire Elektrofi, a biopharmaceutical company, for $900m. "This acquisition marks a pivotal step in Halozyme's evolution. With Elektrofi's Hypercon technology, we are expanding and diversifying our drug delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi's licensing, royalty revenue business model. We look forward to welcoming Elektrofi's talented team as we embark on our next chapter of drug delivery innovation to continue to drive value for all of our stakeholders including our partners, patients, and shareholders," Helen Torley, Halozyme President and CEO.